Effect on Insulin Resistance in Tofogliflozin-treated Japanese Type 2 diabetic patients

Effect on Insulin Resistance in Tofogliflozin-treated Japanese Type 2 diabetic patients - Tofogliflozin and insulin sensitivity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017006

Enrollment

Registered

2015-04-01

Start date

2015-04-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Tofogliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Diagnosed as Type 2 diabetes (2)7=<HbA1c<10% (3)18.5=<BMI<45 (4)20=<informed conscent age<75 (5)Registration inspection before 8 weeks or more, patients are administered without prescription change in the approved dosage regimen of diet and exercise therapy and DPP-4 inhibitors (6)Subjects who give consent document about participation in the clinical study

Exclusion criteria

Exclusion criteria: 1) Has hypersensitivity to tofogliflozin or any other excipient of tofogliflozin 2) With severe ketosis, diabetic coma, or precoma within 6 months 3) With severe infection, pre or post surgery, and serious trauma 4) With severe renal dysfunction 5) With severe liver dysfunction 6) Entered already with another clinical trials (7) Considered as inadequate by the investigator

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in GIR using glucose clamp technique.	—

Countries

Japan

Contacts

Public ContactIkuro Matsuba

Matsuba Medical Clinic Department of Diabetes and Endocrinology

ikuro@matsuba-web.com+810445221678

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026